Metropolis Healthcare Reports 23% Revenue Growth in Q4FY26 Business Update

Metropolis Healthcare Limited (NSE: METROPOLIS; BSE: 542650) has released its provisional business update for the quarter ended March 31, 2026. The company demonstrated strong performance across its diagnostic segments, significantly bolstered by recent acquisitions and a surge in specialized testing.

Group Performance Highlights (Consolidated)

The MHL Group, which includes Core Diagnostics, Scientific Pathology, DAPIC, and Ambika Laboratory, saw a robust expansion:

Revenue Growth: Consolidated revenue grew by approximately 23% Year-on-Year (YoY).

Segment Drivers: Growth was primarily fueled by the TruHealth wellness segment (+25% YoY) and the Specialized testing segment (+29% YoY).

Channel Performance: B2B revenue led the way with a 30% YoY increase, while B2C revenue grew by 19% YoY.

Acquisitions and Margins

Metropolis reported that the integration of laboratories acquired last year is progressing successfully, with synergy benefits now contributing to the bottom line.

Core Diagnostics: Margins are improving, reaching the high single-digit range in Q4FY26.

Strategic Assets: DAPIC, Scientific, and Ambika continue to deliver profit margins that are higher than the company's overall average.

Organic Growth (MHL Organic)*

Excluding the recent acquisitions, the company's organic business remains healthy:

Revenue: Grew by 14.5% YoY, driven by a balanced combination of increased patient volumes and an improved test mix.

Profitability: EBITDA margins improved YoY due to operating leverage and efficiency gains across the network.

Note: The financial results for Q4FY26 are provisional and subject to a statutory audit.

Shares of Metropolis Healthcare Limited was last trading in BSE at Rs. 422.95 as compared to the previous close of Rs. 423.80. The total number of shares traded during the day was 7241 in over 870 trades.

The stock hit an intraday high of Rs. 430.75 and intraday low of 413.00. The net turnover during the day was Rs. 3052417.00.

Source : Equity Bulls

Keywords

MetropolisHealthcare INE112L01020 HealthcareServices Q4FY26 BusinessUpdates